Mustang Bio to Present at the Virtual Fortress Biotech R&D Summit Hosted by B. Riley SecuritiesGlobeNewsWire • 04/04/22
Mustang Bio Reports Full-Year 2021 Financial Results and Recent Corporate HighlightsGlobeNewsWire • 03/23/22
Mustang Bio Announces City of Hope, University of Alabama at Birmingham and Nationwide Children's Hospital Abstract Accepted for Late-Breaker Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2022GlobeNewsWire • 03/09/22
Mustang Bio Completes a $75 Million Debt Financing with Runway Growth CapitalGlobeNewsWire • 03/08/22
Mustang Bio Announces City of Hope MB-105 Prostate Stem Cell Antigen CAR T Data Selected for Presentation at the 2022 American Society of Clinical Oncology Genitourinary Cancers SymposiumGlobeNewsWire • 02/15/22
Mustang Bio Selected as a Bronze Winner in Eighteenth Annual Team Massachusetts Economic Impact AwardsGlobeNewsWire • 02/08/22
Mustang Bio Provides an Update on its IND Application for MB-207, a Lentiviral Gene Therapy for Treatment of X-linked Severe Combined Immunodeficiency (“XSCID”) in Previously Transplanted PatientsGlobeNewsWire • 01/24/22
Mustang Bio Announces MB-106 CD20-Targeted CAR T Data Selected for Presentation at the 2022 Tandem Meetings I Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTRGlobeNewsWire • 01/07/22
Mustang Bio to Participate in Three January 2022 Virtual Investor ConferencesGlobeNewsWire • 01/05/22
Mustang Bio Announces Updated Interim Phase 1/2 Data for MB-106 in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic LeukemiaGlobeNewsWire • 12/13/21
Mustang Bio to Host Key Opinion Leader Webinar on MB-106, a Potential Treatment for B-Cell Non Hodgkin Lymphomas and Chronic Lymphocytic LeukemiaGlobeNewsWire • 12/09/21
Mustang Bio Reports Third Quarter 2021 Financial Results and Recent Corporate HighlightsGlobeNewsWire • 11/12/21
Mustang Bio Announces Exclusive Worldwide License Agreement with Leiden University Medical Centre for Clinical-Stage Lentiviral Gene Therapy with Curative Potential for RAG1 Severe Combined ImmunodeficiencyGlobeNewsWire • 11/10/21
Mustang Bio Announces MB-106 CD20-Targeted CAR T Data Selected for Presentation at 63rd American Society of Hematology (ASH) Annual MeetingGlobeNewsWire • 11/04/21
Mustang Bio Awarded NIH Grant For MB-106 CD20-Targeted CAR T Cell Therapy for Treatment of B-cell non-Hodgkin LymphomasGlobeNewsWire • 11/01/21
Mustang Bio to Participate in Chardan's Virtual 5th Annual Genetic Medicines ConferenceGlobeNewsWire • 09/30/21
Mustang Bio Announces MB-101 (IL13Rα2‐targeted CAR T cells) Scientific Presentations at Upcoming Virtual ConferencesGlobeNewsWire • 09/28/21